TG Therapeutics Q2 net income drops to $7.8 million; revenue rises 70.26% to $240.3 million

• TG Therapeutics posted Q2 2026 revenue of $240.3 million, including BRIUMVI U.S. net product revenue of $227.7 million, up about 64% y/y.
• Net income fell to $7.8 million from $28.2 million a year earlier, as R&D expense climbed to $95.3 million from $31.8 million.
• SG&A expense rose to $82.1 million from $55.6 million, driven by higher marketing and media spend plus commercialization-related personnel costs.
• Raised full-year 2026 revenue target to about $950 million, including BRIUMVI U.S. net product revenue target of about $890-$905 million.
• CEO Michael S. Weiss said BRIUMVI sales are tracking toward an about $1 billion annualized U.S. revenue run rate exiting 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802276) on August 03, 2026, and is solely responsible for the information contained therein.